Introduction
Since the Framingham Heart Study showed that the blood cholesterol level was correlated with the onset of coronary artery diseases 1) , the importance of reducing elevated cholesterol levels to prevent major cardiovascular events has been well established. The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) to prevent the progression of atherosclerosis and the onset of coronary artery disease; however, the Japan Lipid Assessment Program (J-LAP) study showed that the achievement of LDL-C goals specified in the JAS2002GL was not satisfactory in spite of including atorvastatin (50.6%, 53.1%, and 29.2% of patients in category B3, B4, and C, respectively) 9) . In Western countries, rosuvastatin has come into widespread clinical use, because it has been reported to exhibit a stronger LDL-C lowering effect and a higher rate of achieving therapeutic goals than atorvastatin [10] [11] [12] [13] . Recently, it was reported that regression of coronary atherosclerosis requires a substantial reduction of LDL-C along with an increase of high-density lipoprotein cholesterol (HDL-C) by more than 7.5%, and that LDL-C/HDL-C ≤ 2.0 was associated with the possible inhibition of plaque progression or even with plaque regression, and a further effect was expected when LDL-C/HDL-C ≤ 1.5 14) . Although rosuvastatin is expected to be a useful new lipid-lowering drug for high-risk Japanese patients, few reports have compared rosuvastatin with other statins in the Japanese population. In the SUBARU (SUperior Benefit of Aggressive lipid-lowering therapy for high-Risk patients Using statins) study, we compared the achievement of JAS2002GL LDL-C goals and the LDL-C/ HDL-C ratio ≤ 2.0 or ≤ 1.5, the percent changes of lipids (LDL-C, total cholesterol [TC], HDL-C, triglycerides [TG] , and LDL-C/HDL-C ratio), the percent changes of other parameters (high sensitive C-reactive protein [hs-CRP], adiponectin, small dense LDL, and fasting plasma glucose) from baseline to 8 weeks, and safety between rosuvastatin (5 mg/day) and atorvastatin (10 mg/day), which is currently considered to show the most powerful lipid-lowering effect in high-risk patients (category B3, B4, or C) who require active control of their lipid levels.
Subjects and Methods
This open-label, randomized, parallel-group comparative study was performed at 55 institutions between December 2006 and October 2007. The study was performed in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board (IRB) of each institution. Written consent was obtained from all patients before any study-related procedure.
Patients with hypercholesterolemia who had received atorvastatin (10 mg) once daily for at least 4 weeks were enrolled in the present study. They were aged 20 years or more and were classified as being at high risk (JAS2002GL category B3, B4, or C). The JAS2002GL classifies patients with at least 3 risk factors (or with diabetes) into category B3, patients with at least 4 risk factors (or with cerebral infarction) into category B4, and patients with a history of coronary artery diseases into category C 8) . At the time of enrollment, the baseline characteristics of the patients (gender, birth date, and risk factors for atherosclerotic diseases) were investigated. Eligible patients were randomly assigned to receive either rosuvastatin at 5 mg/ day (switched treatment) or atorvastatin at 10 mg/day (continued treatment) using the central registration method, and each treatment was given for 8 weeks (Fig. 1) . Randomization was performed with stratification for the JAS2002GL category (B3, B4, or C) and achievement of LDL-C goals (yes or no).
The exclusion criteria were patients with severe hypertension, patients with type diabetes, patients with familial hypercholesterolemia, patients with the occurrence of cerebrovascular disease or myocardial infarction within the last 3 months, patients with active hepatic disease (alanine aminotransferase [ALT] 100 IU/L, aspartate aminotransferase [AST] 100 IU/L, or bilirubin 2.5 mg/dL), patients with renal dysfunction (serum creatinine ≥ 2.0 mg/dL or creatinine clearance 30 mL/min/1.73 m 2 ), patients with a serum creatine kinase (CK) 1,000 IU/L, patients with hypothyroidism, pregnant or impregnable women, and women who hoped to be pregnant during the study period. Use of other statins, fibrates, or anion exchange resins was prohibited during the study period.
The primary endpoint was the achievement of JAS2002GL LDL-C goals at 8 weeks, which was 120 mg/dL for category B3 and B4 patients and 100 mg/ dL for category C patients 8) . The secondary endpoints were the achievement of JAS2002GL LDL-C goals at 8 weeks in subgroups stratified by baseline characteristics, the percent changes of LDL-C, TC, HDL-C, TG, LDL-C/HDL-C ratio, adiponectin, small dense LDL, hs-CRP, and fasting plasma glucose from baseline to 8 weeks, and achievement of the LDL-C/HDL-C ratio ≤ 2.0 or ≤ 1.5. To assess safety, the incidence and details of adverse events and laboratory abnormalities were investigated. Compliance with treatment was assessed at 4 and 8 weeks by interview. Any change of the dosage regimen of concomitant medication was prohibited during the study. Laboratory tests (including biochemistry tests, hematology tests, urinalysis, serum lipids, and other parameters) were performed after an overnight fast at baseline and at 8 weeks. All laboratory tests were performed by SRL Medisearch Inc. (Tokyo, Japan). LDL-C, TC, TG, and fasting plasma glucose were measured by enzymatic methods, HDL-C by the selective inhibition method, hs-CRP by latex-nephelometry, adiponectin by ELISA, and small dense LDL by relative mobility calculated from a densitogram.
Data analysis was performed by Mebix Inc. (Tokyo, Japan), independently of the study group, which was assigned by the chief investigator to act as the central data center. All efficacy analyses were carried out on the full analysis set. Safety was analyzed on the safety population that consisted of patients who had at least one visit after randomization regardless of taking the study drug. The percent changes of each parameter were calculated from the mean standard deviation. Differences in the percent changes of each parameter and in the achievement of JAS2002GL LDL-C goals or an LDL-C/HDL-C ratio ≤ 2.0 or ≤ 1.5 at 8 weeks were statistically assessed by the t-test and Fisher's exact test, respectively. For imbalance of the baseline variables between groups, their influence on the achievement of JAS2002GL goals was explored by variable selection (stepwise method and method of all possible combinations) of logistic regression analysis. All statistical tests were two-sided, with the level of significance being set at p 0.05.
Results
The disposition of the study population is summarized in Fig. 2 . A total of 446 patients were enrolled in the study, while assignment to medication was performed and treatment was started for 427 patients (214 in the rosuvastatin group and 213 in the atorvastatin group). Among them, 199 patients in the rosuvastatin group and 206 patients in the atorvastatin group completed the study.
The baseline characteristics of the patients assigned to each treatment are summarized in Table 1 . Patients were older in the rosuvastatin than in the atorvastatin group (p 0.05), but there were no appreciable differences of other baseline characteristics between the two groups, including gender, smoking, JAS2002GL categories, complications, cardiovascular risk factors, and the achievement of JAS2002GL LDL-C goals. Treatment compliance was generally good during this study. Poor compliance (compliance rate below 75%) was only three patients in the rosuvastatin group.
Efficacy
At baseline, JAS2002GL LDL-C goals were achieved in 69.7% and 70.5% of the rosuvastatin and atorvastatin groups, respectively ( Table 1) . JAS2002GL goals were achieved in 80.3% of the rosuvastatin group versus 67.3% of the atorvastatin group after 8 weeks, and the achievement rate of the rosuvastatin group was significantly higher (p 0.01) (Fig. 3) .
The results of stratified analysis of the achievement of LDL-C goals according to cardiovascular risk factors (hypertension, diabetes, coronary artery disease, and stroke) and each patient's category of the JAS2002GL (B3 B4 or C) are shown in Fig. 4 . Among patients with hypertension or diabetes, 85.6% LDL-C goal: Category B3 ( 120 mg/dL); B4 ( 120 mg/dL); C ( 100 mg/dL) Fisher's exact test P values show differences between the rosuvastatin and atorvastatin groups.
and 83.0% achieved the LDL-C goals in the rosuvastatin group, respectively, while the corresponding rates for the atorvastatin group were 64.9% and 67.4%, respectively. Both rates were significantly higher in the rosuvastatin group (p 0.001 and p 0.01, respectively). Among the patients in category B3 B4, achievement of LDL-C goals showed a significant difference between the rosuvastatin and atorvastatin groups (82.1% vs. 66.1%, p 0.01). When the levels of lipids and other parameters at baseline and 8 weeks, as well as their percent changes from baseline to 8 weeks, were investigated, it was found that LDL-C, the LDL-C/HDL-C ratio, and fasting plasma glucose showed significant differences between the rosuvastatin and atorvastatin groups (p 0.01 in favor of rosuvastatin for all parameters) ( Table 2) .
The percent change of LDL-C in patients with hypertension, diabetes, and category B3 B4 from the rosuvastatin group was, respectively, 6.7%, 7.9%, and 5.9% from baseline to 8 weeks, while the corresponding rates for the atorvastatin group were 0.2%, 0%, and 1.1%. There were significant differences between the two groups (hypertension: p 0.01, diabetes: p 0.001, category B3 B4: p 0.01) ( Table 3) . The percent change of LDL-C from baseline to 8 weeks stratified by a baseline LDL-C of 100 mg/dL, 100-120 mg/dL, 120-140 mg/dL, 140-160 mg/dL, and 160 mg/dL was, respectively, 2.1%, 7.7%, 8.4%, 20.4%, and 21.4% in the rosuvastatin group, while it was, respectively, 3.2%, 3.6%, 2.2%, 7.4%, and 10.0% in the atorvastatin group. There were significant differences between the groups for LDL-C levels of 100 mg and 140-160 mg (p 0.05 and p 0.01, respectively) ( Table 4 ). The percent change of the LDL-C/HDL-C ratio in patients with hypertension, diabetes and category B3 B4 in the rosuvastatin group was 5.4%, 6.8% and 4.6%, respectively, while the corresponding rates for the atorvastatin group were 3.1%, 2.7% and 1.3%. There were also significant differences between the groups (hypertension and diabetes: p 0.001, category B3 B4: p 0.01) ( Table 5) . Achievement of an LDL-C/HDL-C ratio ≤ 2.0 also showed a significant difference between the rosuvastatin and the atorvastatin groups (70.2% vs. 59.5%, LDL-C goal: Category B3 ( 120 mg/dL); B4 ( 120 mg/dL); C ( 100 mg/dL) CAD: Coronary artery disease Fisher's exact test P values show differences between the rosuvastatin and atorvastatin groups. : category (high-risk patients) of primary prevention in JAS GL2007, : history of CAD of secondary prevention in JAS GL2007 p 0.05) (Fig. 5) . On the other hand, achievement of an LDL-C/HDL-C ratio ≤ 1.5 was noted in 42.4% of the rosuvastatin group and 32.7% of the atorvastatin group (Fig. 5) .
Safety
Safety was analyzed in 415 patients (209 from the rosuvastatin group and 206 from the atorvastatin group). Adverse events were noted in 33 patients from the rosuvastatin group and 31 patients from the atorvastatin group. The incidence of adverse events was 15.8% in the former group and 15.0% in the latter group. All of the adverse events were transient, and none were clinically important.
Adverse events noted in 3 patients or more were increased CK (normal range: 5−97 U/L [male], 32− 180 U/L [female]) in 12 patients (5 from the rosuvastatin group and 7 from the atorvastatin group) and upper respiratory tract inflammation in 10 patients (5 from both treatment groups). A serious adverse event occurred in 1 patient from the rosuvastatin group (hospitalization for treatment of a left tibial plateau fracture), but this was considered to be unrelated to the study drug by the investigator. Treatment was dis- continued because of adverse events in 8 patients from the rosuvastatin group only. Thus, there were no major safety problems in eithes treatment group, and rosuvastatin (5 mg/day) and atorvastatin (10 mg/day) were well tolerated by patients with hypercholesterolemia.
Discussion
It is thought that mortality due to atherosclerotic diseases, including cardiovascular and cerebrovascular disease, will increase in Japan in the near future because of rapid enlargement of the elderly population and westernization of the lifestyle, so there has been a growing demand for more effective prevention and treatment of such diseases. Atherosclerosis is induced and aggravated by the accumulation of various risk factors, among which LDL-C is considered to be the most important. therefore, control of LDL-C has been the main treatment objective for atherosclerosis, and lipid-lowering drugs (especially statins) have played an important role in the management of this (n 55) 127. 7 Table 5 . Percent change of LDL-C/HDL-C ratio from baseline to 8 weeks stratified by risk factors disease.
In the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases (JAS2007GL), which were published in 2007, category B3 and B4 are combined as "primary prevention of high-risk patients" and category C is designated as "secondary prevention patients", but the LDL-C goals are still 120 mg/dL for "primary prevention of high-risk patients" and 100 mg/dL for "secondary prevention patients" 15) . Although LDL-C is the most important target of treatment, control of HDL-C is also considered important according to National Cholesterol Education Program (NCEP) guidelines 16) . Recent studies on the changes of coronary artery plaque after statin therapy have shown that not only the percent reduction of LDL-C but also the change of the LDL-C/HDL-C ratio is related to the percent change of plaque, suggesting that control of this ratio is important for the treatment of plaque and has a direct influence on mortality 14) . In the present study, there was a significant difference of baseline LDL-C levels between the groups, but a significant group-related difference was still detected when the achievement of LDL-C goals was analyzed after adjustment for the difference of baseline LDL-C values (p 0.035, logistic regression analysis). Adjustment for baseline characteristics was also performed in the results of stratified analyses and it was confirmed that significant differences were still detected. Since over 70% of the patients had an LDL-C/HDL-C ratio ≤ 2.0 after treatment with rosuvastatin (5 mg/day), which was more than 10% higher than after treatment with atorvastatin (10 mg/day), rosuvastatin was able to improve both LDL-C and HDL-C. Thus, it seems likely that rosuvastatin would be more useful than atorvastatin for qualitative and quantitative improvement of plaque.
In other Japanese studies, rosuvastatin has been shown to improve TG and HDL-C levels [17] [18] [19] . In the present study, however, marked variations between individual patients meant that these parameters were not significantly different in the rosuvastatin group compared with the atorvastatin group. Since no dietary or lifestyle guidelines were specified in the present study, it is possible that parameters which tend to be influenced by these factors showed great variation as a result; therefore, it is necessary to take these points into consideration when designing future studies.
Many large-scale clinical studies of rosuvastatin have been performed around the world, and this series of studies is called the GALAXY Programme 20) . The ultimate objective of the GALAXY Programme is to verify the inhibitory effect of rosuvastatin on the onset of cardiovascular events, and evidence of the effect of this drug on atherosclerotic plaque has already been obtained. The ASTEROID (a study to evaluate the effect of rosuvastatin on intravascular ultrasoundderived coronary atheroma burden) and METEOR (measuring effects on intima media thickness: an evaluation of rosuvastatin) studies from the GALAXY Programme have shown that rosuvastatin reduces coronary artery plaque and slows the progression of carotid plaque 21, 22) . Based largely on the results of the METEOR study, rosuvastatin has become the only statin indicated to slow the progression of atherosclerosis in patients with hypercholesterolemia in the United States of America. Since the LDL-C/HDL-C ratio was also improved by the administration of rosuvastatin (5 mg/day) in the present study, it can be expected that this drug will control atherosclerotic disease or slow its progression in Japanese patients. Recently, the CORONA (controlled rosuvastatin multinational trial in heart failure) study showed an eight per cent reduction in the combined primary endpoint of cardiovascular death, myocardial infarction or stroke in patients with heart failure taking rosuvastatin at 10 mg/day (p 0.12). Although this improvement did not reach statistical significance, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (n 2193) than in the placebo (n 2564) (p 0.001), and rosuvastatin did not cause safety Fisher's exact test P values show differences between the rosuvastatin and atorvastatin groups.
problems in patients with systolic heart failure 23) . Safety analysis revealed that both rosuvastatin (5 mg/day) and atorvastatin (10 mg/day) were well tolerated in the present study. It was not rejected, however, that patients with less tolerability to atorvastatin were possibly excluded at screening, as we did not assess adverse reactions to atorvastatin before study entry. In addition, several large-scale epidemiological studies of rosuvastatin have already been reported 24, 25) , and it has been confirmed that its safety is similar to that of other statins with respect to the incidence of rhabdomyolysis, myopathy, acute renal failure, or hepatic impairment.
In the present study, rosuvastatin (5 mg/day) exhibited a strong LDL-C lowering effect, as well as a beneficial effect on other lipid parameters (including elevation of HDL-C and reduction of LDL-C/ HDL-C ratio) and fasting plasma glucose. Accordingly, rosuvastatin (5 mg/day) seems to be a useful treatment option for high-risk patients with hypercholesterolemia.
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